A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma

Autor: A. Casado Herraez, Cristina Ligia Cebotaru, Alfredo Zurlo, Riccardo Belli, Alla Lisyanskaya, Nicoletta Colombo, F. Raspagliesi, Jalid Sehouli, M. Romeo Marin, U. De Giorgi, Marcia Hall, S. Mihutiu, Róbert Póka, Janina Markowska, B. Zurawski, J.A. Arranz Arija, Jonathan A. Ledermann, N. Kovalenko, Susana Banerjee, E. Kutarska

Publikováno v: Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f8bd238e689e748849ae583d35aaaa
https://doi.org/10.1093/annonc/mdx440.035